panax japonicus/抗真菌薬

FIELD OF THE INVENTION The present invention relates to a composition for preventing or treating acquired immunodeficiency syndrome (AIDS), comprising one or more of the following: a cell line derived from the cambium of Panax ginseng including wild ginseng and ginseng, and a lysate, an extract and

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates generally to therapeutic products and methods for treatment of sickle cell anemia and its symptomatology, and more specifically to a process for the extraction and isolation of therapeutic compositions from the roots

CROSS-REFERENCE TO RELATED APPLICATIONS The present application is a 35 U.S.C. 371 national stage entry of PCT International Application No. PCT/EP2006/010324 filed on Oct. 26, 2006, claiming benefit of foreign priority to European Patent Application No. EP 05077592 filed on Nov. 14, 2005, both of

FIELD OF THE INVENTION This invention relates to chemical processes of making fractions from North American ginseng (Panax quinquefolium) and compositions containing these fractions. The products of the present invention may be used to stimulate the production of antibodies, or as therapeutics

FIELD OF THE INVENTION This invention relates to chemical processes of making fractions from North American ginseng (Panax quinquefolium) and compositions containing these fractions. The products of the present invention may be used to stimulate the production of antibodies, or as therapeutics

FIELD OF THE INVENTION This invention relates to chemical processes of making fractions from North American ginseng (Panax quinquefolium) and compositions containing these fractions. The products of the present invention may be used to stimulate the production of antibodies, or as therapeutics

FIELD OF THE INVENTION This invention relates to chemical processes of making fractions from North American ginseng (Panax quinquefolium) and compositions containing these fractions. The products of the present invention may be used to stimulate the production of antibodies, or as therapeutics

CROSS REFERENCE TO RELATED APPLICATIONS This application is the National Stage of PCT/EP2008/007357 filed on Sep. 9, 2008, which claims priority under 35 U.S.C. .sctn.119 of German Application No. 10 2008 020 127.8 filed on Apr. 22, 2008, the disclosure of which is incorporated by reference. The

STATEMENT REGARDING PRIOR DISCLOSURES Let it be known that Korean patent application No. 10-2014-0114410 filed on Aug. 29, 2014, and its Korean patent publication No. 10-2016-0026256 published on Mar. 9, 2016, does not apply as prior art to the present application under AIA 35 U.S.C. .sctn.

CROSS-REFERENCE TO RELATED APPLICATIONS This application is a U.S. national phase of International Application No. PCT/KR2009/006523 filed on Nov. 6, 2009, which claims the benefit of Korean Application No. 10-2008-0110086 filed on Nov. 6, 2008, the contents of which are hereby incorporated by

This application is the U.S. National Phase under 35 U.S.C. .sctn.371 of International Application PCT Patent Application No. PCT/KR2004/001941, filed on Aug. 2, 2004, which claims priority to Korean Patent Application No. 10-2004-055088, filed on Jul. 15, 2004, the contents of which are all herein

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention is directed to a method of treatment of kidney failure; in particular, to a method of treatment of diabetes-inducing kidney failure. 2. Description of Related Art The application of Chinese herbal medicine in treatment of